I congratulate myself for an astute call.
$5.40 ~ At the call
$5.80 ~ Currently
$0.40 ~ 7.4% Increase
Most importantly the company future is promising and the Long street wise shareholders will be generously rewarded for not having Weak Hands and panic selling shares on a pullback based upon an insignificant event or set of circumstances.
Long and Strong
Prenzie the Magnificent
It is difficult for small biotechnology companies to become big pharma, especially currently in this M&A era. I doubt if Gilead Sciences were in the same situation as Exelixis is now, that the company could avoid a buyout or merger and emerge to a lofty market cap as Gilead Sciences has managed to do, being the darling of biotechnology companies. Those days may be over, except in rare instances such as two small companies merging.
If the analysts are correct with their closely held information and research findings, their assessments and projections represents a 500% increase in the share price.
The Longs' Reward versus Shorts' Risk Ratio clearly falls in the Longs' camp.
The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information.
GILD RTRX EXEL ALIOF ENZ
November 10, 2015
Valuations are traditionally dependent on earnings potential and past performance. However, in the case of biotech stocks, market watchers and investors base their valuations on the highest possible sales major products could rake in. This leads to wild price swings for the stocks.
However, a variety of factors indicate that the growth potential for the sector remains undiminished. This is why you should buy some of these stocks for growth. Our selection is also backed by a good Zacks Growth Score and Zacks Rank.
We narrowed down our choices with the help of our new style score system.
Our research shows that stocks with a Growth Style Score of ‘A’ or ‘B’ when combined with a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy) offer the best investment opportunities in the growth investing space.
Gilead Sciences Inc. (GILD - Analyst Report) focuses on the discovery, development and commercialization of drugs for several indications.
Gilead Sciences holds a Zacks Rank #2 (Buy) and has a Growth Style Score of ‘B’. The company has expected earnings growth of 51% for the current year.
Retrophin, Inc. (RTRX - Snapshot Report) develops, acquires and commercializes drugs utilized to treat rare diseases.
Retrophin holds a Zacks Rank #2 (Buy) and has a Growth Style Score of ‘B’. The company’s expected earnings growth for the current year is more than 100%. The earnings estimate for the current year has also increased by more than 100% over the last 30 days.
Exelixis, Inc. (EXEL - Snapshot Report) develops small molecule therapies used to treat cancer.
Apart from a Zacks Rank #2 (Buy), Exelixis has a Growth Style Score of ‘B’. The company has expected earnings growth of 40.3% for the current year.
Phase IV clinical trials are conducted after the FDA approves the marketing of a drug by a pharmaceutical company. The purpose of Phase IV research is to examine the long-term effects of drugs over an extended time period for a larger group of people. Phase IV clinical studies are performed to continuously discover more information about these new drugs post marketing.
Kate George, Editor — November 11, 2015, 11:02 AM EDT
Earlier this week, Zogenix posted Q3 earnings that beat expectations. The company posted quarterly revenues of $9.1 million; higher than the consensus estimates of $5.9 million. Based on this strong performance, Difei Yang of Brean Capital maintained a Buy rating for the stock with a price target of $28.
Yang highlighted that the reason for the strong Q3 performance is an increase in manufacturing revenue due to the increase in shipments of Sumavel DosePro to Endo International Plc. Sumavel DosePro is a needle-free injection for treating acute migraine and cluster headaches.
For the next year, Yang will be looking at various catalysts, including the approval for the Investigational New Drug application, or IND, of ZX008. The pipeline treatment is a low-dose formulation of fenfluramine that can potentially become a transformational treatment for Dravet syndrome; a rare form of epilepsy which begins in infancy. While fenfluramine has had a complicated history with the FDA, Yang is confident that an IND will be approved. Yang is also looking forward to a Phase III clinical trial for ZX008 with a read-out expected in late 2016.
Furthermore, Yang is looking forward to the licensing agreement for Relday in the first half of 2016. Relday is an antipsychotic product for the treatment of schizophrenia. Before moving Relday into phase III testing, the company has strategically decided to engage a global strategic development and commercialization partner. If the deal is successful, Yang expects an incremental upside for the company.